EPISODE · Jan 31, 2025 · 22 MIN
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 13 cGMP Fundamentals and Their Societal Impact
from Cannabinoid and Psychedelic Pharmacology and Drug Development
This podcast episode explores the fundamentals of Current Good Manufacturing Practices (cGMP) in pharmaceutical production, with a special focus on emerging cannabinoid and psychedelic therapies. The discussion covers key aspects of cGMP including documentation, quality control, facility standards, and personnel training. The episode delves into historical examples like the thalidomide tragedy to illustrate why strict manufacturing standards are crucial. It also addresses current challenges in maintaining product safety, including the management of impurities and the importance of third-party testing. The conversation emphasizes how cGMP helps build trust in new therapeutic areas while ensuring consistent product quality and safety.
NOW PLAYING
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 13 cGMP Fundamentals and Their Societal Impact
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.